Norge -
norsk -
Statens legemiddelverk
isocare vet 1000 mg/ g
ecuphar nv - isofluran - væske til inhalasjonsdamp - 1000 mg/ g
Den europeiske union -
norsk -
EMA (European Medicines Agency)
kisplyx
eisai gmbh - lenvatinibmesilat - karsinom, nyrecelle - antineoplastiske midler - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
Norge -
norsk -
Statens legemiddelverk
apocillin 250 mg/ ml
actavis group ptc ehf (1) - fenoksymetylpenicillinkalium - granulat til dråper, oppløsning - 250 mg/ ml
Norge -
norsk -
Statens legemiddelverk
diprotit 0.05 % w/w
evolan pharma ab - betametasondipropionat - Øredråper, oppløsning - 0.05 % w/w
Den europeiske union -
norsk -
EMA (European Medicines Agency)
actrapid
novo nordisk a/s - humant insulin - sukkersyke - legemidler som brukes i diabetes - behandling av diabetes mellitus.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.